Icon Plc (ICLR) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Icon Plc (ICLR) stock forecast summary
On Oct. 16, 2026, ICLR is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Icon Plc is a large-cap company with a market capitalization of $13.13B. It ranks number 5 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast.
For ICLR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 60.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 45.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ICLR included.
Follow ICLR freeICLR price chart and AI forecast
How ICLR ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Icon Plc (ICLR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | ICLR | Rank |
|---|---|---|
| Market Cap | $13.13B | 5/15 |
| P/E Ratio | 36.76x | – |
| P/B Ratio | 1.40x | 7/10 |
| EPS | $4.63 | – |
| Book Value/Share | $121.55 | – |
Profitability & Margins
| Metric | ICLR | Rank |
|---|---|---|
| ROE | 3.9% | 4/9 |
| ROA | 2.2% | 4/11 |
| ROIC | 4.9% | 7/11 |
| Gross Margin | 25.4% | 5/7 |
| Operating Margin | 7.5% | 5/13 |
| Net Margin | 4.5% | 4/10 |
| EBT Margin | 6.9% | 4/13 |
| Tax Rate | 10.0% | – |
Financial Health
| Metric | ICLR | Rank |
|---|---|---|
| Current Ratio | 0.95x | 7/16 |
| D/E Ratio | 0.75x | 7/11 |
| Financial Leverage | 1.75x | 7/10 |
| Interest Coverage | 2.2x | 6/13 |
| Working Capital | -$186M | 13/15 |
Cash Flow
| Metric | ICLR | Rank |
|---|---|---|
| Operating Cash Flow | $982M | 3/15 |
| OCF Growth YoY | -20.0% | 4/5 |
Operational Efficiency
| Metric | ICLR | Rank |
|---|---|---|
| Payables Period | 7 days | 5/6 |
Income Statement
| Metric | ICLR | Rank |
|---|---|---|
| Operating Income | $607M | 3/15 |
| Net Income | $363M | 4/12 |
| SG&A Expense | $797M | 3/12 |
| Cost of Goods Sold | $6.08B | 2/8 |
Dividend & Shareholder Information
| Metric | ICLR | Rank |
|---|---|---|
| Shares Outstanding | 77M | – |
| Net Income Growth | -52.2% | – |
| EPS Growth | -49.6% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3.75B | 22.9% of assets |
| Cash & Short-term Investments | $928M | 5.7% of assets |
| Accounts Receivable | $1.46B | 8.9% of assets |
| Total Liabilities | $7.02B | 42.8% of assets |
| Short-term Debt | $3.82B | 23.3% of assets |
ICLR quarterly financials and insider trading
Icon Plc (ICLR) industry peers
Companies classified under the same SEC industry code as Icon Plc (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ICLR Icon Plc | ▶ | $13.13B |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▶ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $27M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $2M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where ICLR sits on the market map
Icon Plc (ICLR) stock news
Loading...
Icon Plc (ICLR) stock forecast FAQ
What is the Icon Plc (ICLR) stock forecast?
On Oct. 16, 2026, ICLR is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Icon Plc stock predictions?
For ICLR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 60.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 45.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Icon Plc forecasts updated?
Icon Plc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Icon Plc's industry peers?
16 issuers in our coverage, ICLR included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.